This study focuses on Fetal Growth Restriction, a condition where an unborn baby is smaller than expected or growing at an abnormal rate during pregnancy. The research examines the effectiveness of enoxaparin sodium, a medication given as an injection under the skin, in treating early stages of this condition. This medication belongs to a group of drugs called low molecular weight heparins, which are commonly used to prevent blood clots.
The purpose of this study is to determine if this treatment can help extend the time babies with growth restriction can stay in the womb before delivery is necessary. The medication being tested is Enoxaparin Rovi, which comes in pre-filled syringes containing 4,000 international units (40 mg) of the active substance. Participants will receive daily injections under the skin for up to 24 weeks during their pregnancy.
During the study, various aspects of both the mother’s and baby’s health will be monitored through regular check-ups. These include checking the blood flow to the baby and through the placenta, tracking the baby’s growth, and monitoring the mother’s health throughout pregnancy. The study will also look at important outcomes such as the baby’s birth weight, overall health at birth, and any complications that may occur during pregnancy or delivery.
Portugal 